29
Participants
Start Date
February 10, 2020
Primary Completion Date
April 26, 2022
Study Completion Date
April 26, 2022
Pimavanserin
Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
AU Movement and Memory Disorders, Augusta
Accel Research Sites - Brain and Spine Institute, Port Orange
Global Health Research Center, Inc., Miami Lakes
Quantum Laboratories, Inc., Pompano Beach
Premier Clinical Research Institute, Inc., Miami
Infinity Clinical Research, LLC, Sunrise
Premiere Research Institute at Palm Beach Neurology, West Palm Beach
Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte
KCA Neurology, Franklin
The Orthopedic Foundation, New Albany
Neurology Diagnostics, Inc., Dayton
Central States Research, Tulsa
Neurological Associates of North Texas, Dallas
Movement Disorders Center of Arizona, Scottsdale
Neurology Center of North Orange County, Fullerton
Maine Medical Partners Neurology, Scarborough
Wentworth Health Partners Coastal Neurology Services, Dover
Bio Behavioral Health, Toms River
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY